

## Press Release

### **Revenue from operations up by 14% (1<sup>st</sup> Quarter FY 2026 Consolidated Results)**

**Mumbai, 28<sup>th</sup> July, 2025:** Ajanta Pharma Ltd., a specialty pharmaceutical formulation company today reported its excellent performance for 1<sup>st</sup> quarter ended 30<sup>th</sup> June 2025.

#### **Q1 FY 2026 performance highlights (compared to Q1 FY 2025):**

- Revenue from operations at **Rs. 1,303 cr.** against Rs. 1,145 cr.; **up 14%.**
- EBITDA at **Rs. 351 cr.** against Rs. 330 cr.; up 6%; **EBITDA at 27%.**
- Profit after tax at **Rs. 255 cr.** against Rs. 246 cr.; up 4%; **PAT at 20%.**
- The mark-to-market forex loss stood at Rs. 25 cr. Excluding this impact, EBITDA stood at Rs. 376 cr., reflecting a 14% growth, with an EBITDA margin of 29%. PAT grew by 12%, with a PAT margin of 21%.
- Cashflow from operations (CFO) was Rs. 282 cr., EBITDA to CFO conversion of 80%.
- Free cashflow (FCF) was Rs. 209 cr., FCF to PAT conversion of 82%.
- ROCE stood at a healthy level of 33% and RONW at 26%.

#### **Segment wise performance:**

(Rs. cr.)

Markets	Q1		Gwth%
	FY 2025	FY 2026	
<b>Branded Generics</b>			
India	₹ 353	₹ 409	16%
Asia	₹ 277	₹ 304	10%
Africa	₹ 230	₹ 228	-1%
<b>Sub-Total</b>	<b>₹ 860</b>	<b>₹ 941</b>	<b>9%</b>
<b>US Generic</b>	<b>₹ 228</b>	<b>₹ 310</b>	<b>36%</b>
<b>Africa Institution</b>	<b>₹ 42</b>	<b>₹ 38</b>	<b>-8%</b>
<b>Total</b>	<b>₹ 1,130</b>	<b>₹ 1,289</b>	<b>14%</b>

As per **IQVIA MAT June 2025**, our India branded generic performance exceeded IPM growth by **29%**. The higher growth came from **Volumes increase**, which exceeded IPM by **73%** & **New launches**, which exceeded IPM by **46%**.

Therapy	Growth %	
	IPM	Ajanta
Cardiology	12%	8%
Ophthalmology	5%	9%
Dermatology	9%	13%
Pain Management	7%	10%
<b>Overall</b>	<b>8%</b>	<b>10%</b>

**ANDA status** as at the end of Q1 FY 2026 is as below:

Particulars	Q1 FY 2026
Filed	Nil
Approval received	1
Launched	1
Total ANDA's commercialized	47
Awaiting approval with US FDA	21
Tentative approval	2

#### R&D expense:

(Rs. cr.)

Particulars	FY 2025	FY 2026	% to Revenue
Q1	₹ 51	₹ 56	4%

#### About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. Company has ground presence in each of these 30+ countries. Many of company's products are 1st to market and are leading in their sub-therapeutic segments. Company also has presence in USA in generic business and institution business in Africa.

Company's state of the art R&D centre is in Mumbai. Company has 7 world class manufacturing facilities located in India.

For the Last 3 financial years, company has posted healthy revenue CAGR of 11% and even stronger PAT CAGR of 25%.

## **Earnings Conference Call**

The Company will host an Earnings Conference Call at 1600 hrs. IST (1830 hrs. SST/HKT, 1130 hrs. BST, 0630 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at [www.ajantapharma.com](http://www.ajantapharma.com).

### **Dial-in Information**

<b>Date and Time</b>	<b>July 28, 2025 at</b> 1600 – 1700 hrs IST 1830 – 1930 hrs SST/HKT 1130 – 1230 hrs BST 0630 – 0730 hrs US ET
<b>Dial-in Numbers</b>	
<b>Diamond pass link for faster access</b>	Click <a href="#">here</a> to register
Universal Access	Primary Access: <b>(+91 22 6280 1542)</b> <b>(+91 22 7115 8372)</b>
International Toll Free	USA: <b>18667462133</b> UK: <b>08081011573</b> Hong Kong: <b>800964448</b> Singapore: <b>8001012045</b>

### **For convenience and faster connectivity to the conference, kindly follow the below steps:**

1. Register through the Diamond pass link.
2. You will receive a calendar invite along with a passcode and a PIN number. The passcode and PIN will be activated 30 minutes prior to the conference scheduled time.
3. Dial the 'conference Dial-in number' you will receive on your email.
4. On system prompt dial the PASSCODE followed by # key.
5. On system prompt enter the PIN followed by # key.
6. If the line gets disconnected, you need to dial the 'conference dial-in number' again and follow the necessary steps.

### **Playback of Earnings Conference Call audio:**

Playback of the earnings call will be available 120 minutes after the end of the call on our website ([www.ajantapharma.com](http://www.ajantapharma.com)).

For more details visit [www.ajantapharma.com](http://www.ajantapharma.com)

For regular updates follow us on x.com – <https://x.com/AjantaPharmaLtd>

### **For specific queries, contact:**

**Rajeev Agarwal** Tel: +91 22 6060 9706 Email: [rajeev.agarwal@ajantapharma.com](mailto:rajeev.agarwal@ajantapharma.com)

**Abhineet Kumar** Tel: +91 22 6060 9721 Email: [abhineet.kumar@ajantapharma.com](mailto:abhineet.kumar@ajantapharma.com)

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

### **Safe Harbour Statement**